Modality
Degrader
MOA
CAR-T BCMA
Target
GPRC5D
Pathway
T-cell
FSGSNMOSD
Development Pipeline
Preclinical
~Apr 2019
→ ~Jul 2020
Phase 1
Oct 2020
→ Jun 2030
Phase 1Current
NCT04156265
1,734 pts·NMOSD
2020-10→2030-06·Completed
1,734 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-06-084.2y awayPh2 Data· NMOSD
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1/2
Complet…
Catalysts
Ph2 Data
2030-06-08 · 4.2y away
NMOSD
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04156265 | Phase 1/2 | NMOSD | Completed | 1734 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C |